WHO Prequalification Programme launches new EOI
28th February 2008
In December 2007, the World Health Organization (WHO) launched a second invitation to manufacturers of reproductive health (RH) products to submit an Expression of Interest (EOI) for product evaluation to its Prequalification Programme. The aim of this second EOI is to increase the range of selected products and sources available in relation to RH to include:
- Oral hormonal contraceptives: ethinylestradiol + levonrgesrtel
- Injectable hormonal contraceptives: medroxyprogesterone acetate
- Prevention and treatment of postpartum hemorrhage: oxytocin
- Prevention and treatment of eclampsia: magnesium sulphate
These products are included in the WHO Model List of Essential Medicines, the WHO reproductive health guidelines, and the WHO Integrated Management of Pregnancy and Childbirth (IMPAC) guideline. Click here to read more about the EOI.
The first invitation for EOI for RH products was published in October 2006. Click here to read this.